Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier

https://doi.org/10.1016/0014-2999(92)90593-SGet rights and content

Abstract

Recently several novel nonpeptide antagonists of angiotensin II (Ang II) have been identified. One of these, losartan potassium (formerly DuP 753) was developed as an orally active and highly selective antagonist for Ang II. As it is inhibited by sulfhydryl agents, it is specific for the AT1 receptor subtype. Since Ang II has both central and peripheral effects, we investigated whether losartan, given p.o. chronically, crosses the blood-brain barrier. The effects of chronic administration of losartan orally (p.o.) at 3 mg/kg per day for three days on the dipsogenic and pressor responses to a pre-established dose of Ang II i.v.t. (50 ng) were studied. Three series of experiments were carried out using conscious normotensive Sprague-Dawley rats. The rats were injected with Ang II intraventricularly (i.v.t.) befire and after treatment of losartan p.o. and blood pressure and drinking responses measured. The experiments established that 3 mg/kg losartan p.o. for 3 days antagonized pressor effects of Ang II intravenously (i.v.), but did not antagonize the pressor or drinking effects of Ang II i.v.t. Daily water intake significantly increased with chronic losartan p.o.. Since chronic administration of losartan p.o. was able to block the effects of Ang II i.v. but had no effect on Ang II i.v.t. we conclude that losartan potassiu, does not readily cross the blood-brain barrier using this dose regimen.

References (22)

  • J.E. Falcon et al.

    Effects of intraventricular angiotensin II mediated by the sympathetic nervous system

    Am. J. Physiol.

    (1978)
  • Cited by (68)

    • Targeting renin–angiotensin system

      2023, Angiotensin: From the Kidney to Coronavirus
    • Angiotensin II receptor type 1 blockade improves hyporesponsiveness to vasopressors in septic shock

      2021, European Journal of Pharmacology
      Citation Excerpt :

      We cannot rule out that the hypotension induced by higher dose of losartan is promoting inadequate tissue perfusion and oxygen delivery. Interestingly, previous studies using 3 mg/kg of losartan have suggested that the drug does not cross the blood-brain barrier (Bui et al., 1992). On the other hand, losartan at doses of 10 and 45 mg/kg promotes antidepressant-like effect (Diniz et al., 2018).

    • Hypotensive and vasorelaxant effects of (E) - Methyl isoeugenol: A naturally occurring food flavour

      2014, Food and Chemical Toxicology
      Citation Excerpt :

      Meanwhile, alterations in these parameters could be mediated centrally or peripherally. Centrally acting cardiovascular drugs are considered to target I1-imidazoline receptors and/or α2-adrenoceptors within the rostral ventrolateral medulla (RVLM) towards the control of sympathetic outflow and blood pressure (Bui et al., 1992; Guyenet, 1997; Haxhiu et al., 1994). It has been established experimentally that oral administration of losartan antagonized pressor effects elicited by intravenous treatment with Ang II, but did not antagonize the pressor effects of intracerebroventricular treatment of Ang II (Bui et al., 1992).

    View all citing articles on Scopus
    View full text